Suppression of disease causingnonsense mutations by targeted mRNA pseudouridylation
通过靶向 mRNA 假尿苷化抑制引起无义突变的疾病
基本信息
- 批准号:9805188
- 负责人:
- 金额:$ 16.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Aminoglycoside AntibioticsAnticodonApplications GrantsAttentionBreast CarcinomaCancer EtiologyCancer cell lineCell LineCellsClinicalCodeCodon NucleotidesCoupledCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDevelopmentDiseaseElementsEngineeringEnzymesEpithelial CellsGenesGenetic DiseasesGenetic TranscriptionGoalsHumanHuman GeneticsInheritedLengthMalignant NeoplasmsMass Spectrum AnalysisMeasuresMediatingMessenger RNAModificationMonitorMutationNonsense CodonNonsense MutationNucleoplasmNucleotidesPrimer ExtensionProductionProtein p53ProteinsPseudouridineRNAReporter GenesReverse Transcriptase Polymerase Chain ReactionRibosomal RNARibosomesSignal TransductionSiteSmall Nuclear RNASpecificityStep TestsStructureSystemTP53 geneTerminator CodonTestingTransfectionTransfer RNATranslationsUntranslated RNAUridineWorkYeastsbeta Globincancer typechemical propertyclinically relevantcystic fibrosis patientsestablished cell lineexperiencehuman diseaseimprovedmRNA Decaynovel strategiesnovel therapeuticsprematurerelease factor
项目摘要
In this exploratory grant application, we propose to fully develop a novel approach, namely, targeted
RNA pseudouridylation, to suppress nonsense mutations in genes that cause diseases (e.g.,
nonsense mutations in the CFTR gene that cause Cystic Fibrosis, and nonsense mutations in p53
gene that cause various types of cancer). This project, if successful, will constitute a giant step
toward our ultimate goal of developing novel therapeutic treatment for a number of genetic disorders
and certain types of cancer caused by nonsense mutations. We propose to carry out this project
under two specific aims.
Aim 1. To improve the efficiency of RNA-guided pseudouridylation in human cells. We will improve
the efficiency of targeted mRNA pseudouridylation by identifying a better modifying enzyme
(specifically, a better box H/ACA guide RNA). We will focus on the three elements within the guide
RNA that have been identified (by our lab and other labs) to be important for directing
pseudouridylation, and construct a perfect box H/ACA guide RNA. We will also engineer the guide
RNA by adding a nucleoplasmic localization signal, thus targeting the guide RNA (and RNP) to the
nucleoplasm where mRNA is synthesized and matures. Finally, we will increase box H/ACA RNA
expression level, thus raising its concentration in the nucleoplasm of human cells. In doing so, we
believe we will be able to create a super guide RNA that can efficiently direct site-specific mRNA
pseudouridylation.
Aim 2. To directly target the PTC within a disease gene in human disease cell lines. Using an
designer box H/ACA RNA (especially when the improved super box H/ACA RNA identified in Aim 1
is available), we will directly target the premature termination codon (PTC, resulting from nonsense
mutations) within the CFTR mRNA in a CF cell line and within the p53 mRNA in a human cancer cell
line. The efficiency of guide RNA transfection and its expression level in transfected cells will be
measured. Site-specific pseudouridylation at the PTC of mRNAs will also be quantified. Furthermore,
nonsense suppression, including the suppression of NMD (nonsense-mediated mRNA decay) and
PTC read-through, will be monitored. In short, this proposal presents a potential novel approach to
treat many genetic diseases and certain types of cancer associated with nonsense mutations.
在这个探索性的资助申请中,我们建议充分开发一种新方法,即有针对性的
RNA 假尿苷化,抑制导致疾病的基因中的无义突变(例如,
导致囊性纤维化的 CFTR 基因中的无义突变和 p53 中的无义突变
导致各种癌症的基因)。该项目如果成功,将迈出一大步
实现我们的最终目标,即开发针对多种遗传性疾病的新型治疗方法
以及由无义突变引起的某些类型的癌症。我们建议开展这个项目
在两个具体目标下。
目的 1. 提高人类细胞中 RNA 引导的假尿苷化的效率。我们会改进
通过鉴定更好的修饰酶来提高靶向 mRNA 假尿苷化的效率
(具体来说,更好的盒 H/ACA 引导 RNA)。我们将重点关注指南中的三个要素
已(由我们的实验室和其他实验室)鉴定出对指导很重要的 RNA
假尿苷化,并构建完美的盒式 H/ACA 引导 RNA。我们还将设计指南
RNA 通过添加核质定位信号,从而将向导 RNA(和 RNP)靶向
核质是 mRNA 合成和成熟的地方。最后,我们将增加盒H/ACA RNA
表达水平,从而提高其在人体细胞核质中的浓度。这样做,我们
相信我们将能够创造出一种超级引导RNA,可以有效地指导位点特异性mRNA
假尿苷化。
目标 2. 直接靶向人类疾病细胞系中疾病基因内的 PTC。使用
设计盒 H/ACA RNA(特别是当目标 1 中鉴定出改进的超级盒 H/ACA RNA 时)
可用),我们将直接针对提前终止密码子(PTC,由废话产生)
CF 细胞系中的 CFTR mRNA 内和人类癌细胞中的 p53 mRNA 内的突变)
线。指导RNA转染效率及其在转染细胞中的表达水平为
测量。 mRNA PTC 处的位点特异性假尿苷化也将被量化。此外,
无义抑制,包括抑制 NMD(无义介导的 mRNA 衰减)和
PTC 通读将受到监控。简而言之,该提案提出了一种潜在的新颖方法
治疗许多遗传疾病和与无义突变相关的某些类型的癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YI-TAO YU其他文献
YI-TAO YU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YI-TAO YU', 18)}}的其他基金
Pseudouridine-mediated branch site recognition/selection during pre-mRNA splicing
前 mRNA 剪接过程中假尿苷介导的分支位点识别/选择
- 批准号:
10383755 - 财政年份:2020
- 资助金额:
$ 16.75万 - 项目类别:
Pseudouridine-mediated branch site recognition/selection during pre-mRNA splicing
前 mRNA 剪接过程中假尿苷介导的分支位点识别/选择
- 批准号:
10612829 - 财政年份:2020
- 资助金额:
$ 16.75万 - 项目类别:
Pseudouridine-mediated branch site recognition/selection during pre-mRNA splicing
前 mRNA 剪接过程中假尿苷介导的分支位点识别/选择
- 批准号:
10231213 - 财政年份:2020
- 资助金额:
$ 16.75万 - 项目类别:
Pseudouridine-mediated branch site recognition/selection during pre-mRNA splicing
前 mRNA 剪接过程中假尿苷介导的分支位点识别/选择
- 批准号:
10026485 - 财政年份:2020
- 资助金额:
$ 16.75万 - 项目类别:
Expanding the genetic code by targeted pseudouridylation
通过靶向假尿苷化扩展遗传密码
- 批准号:
8550118 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
Expanding the genetic code by targeted pseudouridylation
通过靶向假尿苷化扩展遗传密码
- 批准号:
8419298 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
Regulation of telomerase activity and aging by 2'-O-methylation in telomerase RNA
端粒酶RNA中2-O-甲基化对端粒酶活性和衰老的调节
- 批准号:
8516934 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
Expanding the genetic code by targeted pseudouridylation
通过靶向假尿苷化扩展遗传密码
- 批准号:
8914641 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
Expanding the genetic code by targeted pseudouridylation
通过靶向假尿苷化扩展遗传密码
- 批准号:
8720024 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
Regulation of telomerase activity and aging by 2'-O-methylation in telomerase RNA
端粒酶RNA中2-O-甲基化对端粒酶活性和衰老的调节
- 批准号:
8242209 - 财政年份:2012
- 资助金额:
$ 16.75万 - 项目类别:
相似海外基金
Determining how 2'-O-methylations in the eukaryotic anticodon loop region of tRNA are formed and how they affect translation
确定 tRNA 真核反密码子环区域中 2-O-甲基化的形成方式以及它们如何影响翻译
- 批准号:
10438971 - 财政年份:2018
- 资助金额:
$ 16.75万 - 项目类别:
Elucidation of reaction mechanism for post-transcriptional modification at tRNA anticodon region
阐明 tRNA 反密码子区域转录后修饰的反应机制
- 批准号:
20687007 - 财政年份:2008
- 资助金额:
$ 16.75万 - 项目类别:
Grant-in-Aid for Young Scientists (A)
Codon-anticodon coevolution in invertebrate mitochondrial genomes
无脊椎动物线粒体基因组中的密码子-反密码子协同进化
- 批准号:
370096-2008 - 财政年份:2008
- 资助金额:
$ 16.75万 - 项目类别:
University Undergraduate Student Research Awards
Role of the Elongator complex in tRNA anticodon modification and intracellular stress signaling (B02)
Elongator 复合物在 tRNA 反密码子修饰和细胞内应激信号传导中的作用 (B02)
- 批准号:
5447893 - 财政年份:2005
- 资助金额:
$ 16.75万 - 项目类别:
Collaborative Research Centres
THE ANTICODON AND ITS INFLUENCE ON TRNA IDENTITY
反密码子及其对 TRNA 身份的影响
- 批准号:
3045064 - 财政年份:1990
- 资助金额:
$ 16.75万 - 项目类别:
THE ANTICODON AND ITS INFLUENCE ON TRNA IDENTITY
反密码子及其对 TRNA 身份的影响
- 批准号:
3045063 - 财政年份:1990
- 资助金额:
$ 16.75万 - 项目类别:
Study on the biosynthesis of the modified uridine derivatives at the first position of the anticodon of tRNA
tRNA反密码子第一位修饰尿苷衍生物的生物合成研究
- 批准号:
61571061 - 财政年份:1986
- 资助金额:
$ 16.75万 - 项目类别:
Grant-in-Aid for General Scientific Research (C)














{{item.name}}会员




